Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by equities researchers at TheStreet from a “c-” rating to a “d+” rating in a research report issued to clients and investors on Wednesday, TheStreetRatingsTable reports.
Several other research analysts have also weighed in on TEVA. UBS Group reissued a “neutral” rating and issued a $11.00 price objective (down from $15.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 10th. JPMorgan Chase & Co. restated a “hold” rating and issued a $10.00 target price on shares of Teva Pharmaceutical Industries in a research note on Sunday, March 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $11.08.
TEVA stock opened at $11.53 on Wednesday. The stock has a 50-day simple moving average of $10.63. Teva Pharmaceutical Industries has a 1-year low of $8.44 and a 1-year high of $13.30. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.66 and a current ratio of 1.03. The company has a market cap of $12.59 billion, a price-to-earnings ratio of -3.18, a PEG ratio of 0.89 and a beta of 1.46.
In other Teva Pharmaceutical Industries news, VP Eric Drape sold 40,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, May 21st. The stock was sold at an average price of $11.01, for a total transaction of $440,400.00. Following the completion of the transaction, the vice president now owns 33,128 shares in the company, valued at approximately $364,739.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP David Matthew Stark sold 37,884 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, May 11th. The shares were sold at an average price of $10.22, for a total value of $387,174.48. Following the transaction, the vice president now owns 40,858 shares of the company’s stock, valued at approximately $417,568.76. The disclosure for this sale can be found here. Insiders have sold a total of 205,128 shares of company stock valued at $2,255,252 in the last quarter. Company insiders own 0.56% of the company’s stock.
Several institutional investors have recently bought and sold shares of the business. Schroder Investment Management Group bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $359,000. Principal Financial Group Inc. lifted its position in shares of Teva Pharmaceutical Industries by 8.1% during the 1st quarter. Principal Financial Group Inc. now owns 128,772 shares of the company’s stock worth $1,486,000 after buying an additional 9,631 shares in the last quarter. Axiom Investment Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $353,000. Factorial Partners LLC lifted its position in shares of Teva Pharmaceutical Industries by 1,054.0% during the 1st quarter. Factorial Partners LLC now owns 1,788,700 shares of the company’s stock worth $155,000,000 after buying an additional 1,633,700 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Teva Pharmaceutical Industries by 527.2% during the 1st quarter. Squarepoint Ops LLC now owns 660,109 shares of the company’s stock worth $7,618,000 after buying an additional 554,855 shares in the last quarter. 52.60% of the stock is currently owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Back-End Load
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.